Detalhe da pesquisa
1.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer
; 21(1): 73, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451293
2.
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Eur J Haematol
; 107(4): 466-474, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272773
3.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Br J Haematol
; 190(2): 189-197, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163180
4.
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Blood Cancer J
; 13(1): 153, 2023 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752128
5.
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Cancer Med
; 7(8): 4132-4145, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29931775
6.
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.
Int J Lab Hematol
; 43(5): e244-e247, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33452712